Elsevier

Biochemical Pharmacology

Volume 49, Issue 4, 14 February 1995, Pages 453-460
Biochemical Pharmacology

Research paper
Ethylmorphine o-deethylation in isolated rat hepatocytes: Involvement of codeine o-demethylation enzyme systems

https://doi.org/10.1016/0006-2952(94)00481-ZGet rights and content

Abstract

The O-dealkylation of ethylmorphine (EM) and codeine (CD) to morphine (M) co-segregates with debrisoquine/sparteine genetic polymorphism in man. CD O-demethylation is catalysed by cytochrome P450 2D1 (CYP2D1) in rats. In the present study, the O-deethylation of EM was examined and compared with that of CD in suspensions of freshly-isolated hepatocytes prepared by a collagenase method from Wistar rats with and without CYP2D1 inhibitors. Isolated hepatocytes were also prepared from Dark Agouti (DA) rats deficient in CYP2D1, and were incubated with EM or CD. EM, CD and their metabolites were quantified by HPLC with UV detection. EM had a similar pattern of metabolism to that of CD in suspensions of hepatocytes from Wistar rats. Both EM and CD were O-dealkylated to form M plus morphine-3-glucuronide (M3G) and N-demethylated to form norethylmorphine (NEM) or norcodeine (NCD), respectively, which were further metabolized to normorphine (NM) and finally glucuronidated to normorphine-3-glucuronide (NM3G). As compared to hepatocytes from Wistar rats, DA rats were characterized by a markedly decreased formation (70~75% reduction) of M plus M3G from both EM and CD. Quinine, quinidine, propafenone and sparteine all inhibited EM O-deethylation as well as CD O-demethylation. Quinine was the most potent inhibitor of both these O-dealkylations (Ki = 0.2 μM for both EM and CD, respectively). Quinine as well as the other inhibitors inhibited both EM and CD O-dealkylation competitively and with small differences in Ki versus EM and CD, respectively. The metabolism of EM to M plus M3G and that of CD to M plus M3G was highly correlated when results from the various separate cell suspensions were plotted. In conclusion all findings indicated that the enzyme responsible for O-demethylation of CD, CYP2D1 was also responsible for the O-deethylation of EM to M.

References (37)

  • N Kerry et al.

    Primary and secondary oxidative metabolism of dextromethorphan: In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes

    Biochem Pharmacol

    (1993)
  • P Dayer et al.

    Enzymaticbasis of the debrisoquine/sparteine type genetic polymorphism of drug oxidation-characterization of bufuralol 1′-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency

    Biochem Pharmacol

    (1987)
  • S Kobayashi et al.

    The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man

    Biochem Pharmacol

    (1989)
  • H Gjerde et al.

    A case of high opiate tolerance: implications for drug analyses and interpretations

    Int J Leg Med

    (1991)
  • Å Ripel et al.

    Morphine formation after intake of ethylmorphine

    Pharmacol Toxicol

    (1992)
  • DE Nerland et al.

    Species, sex and developmental difference in the O- and N-dealkylation of ethylmorphine by hepatic microsomes

    Drug Metab Dispos

    (1978)
  • A Rane et al.

    Ethylmorphine O-deethylation cosegregates with the debrisoquine genetic metabolic polymorphism

    Clin Pharmacol Ther

    (1992)
  • TK Adler et al.

    The metabolic fate of codeine in man

    J Pharmacol Exp Ther

    (1955)
  • Cited by (0)

    Part of this work was presented at the 9th International Symposium on Microsomes and Drug Oxidations, Jerusalem, July 1992.

    View full text